“With Tempus’ unmatched expertise, depth, and broad reach, this collaboration strengthens our shared mission to revolutionise patient care and drive breakthroughs in the field of oncology.” ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... and NCI Community Oncology Research Programs. “Deep 6’s impressive integration infrastructure is well-suited to complement our ...

Deidentified records from patients with a histologic diagnosis of conventional, dedifferentiated, or mesenchymal chondrosarcoma sequenced by the Tempus xT DNA assay were included. Microsatellite ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ ... as "one of the largest libraries of clinical and molecular oncology data in the world." Many potential investors, however, are ...

This collaboration not only expands Tempus AI's data assets in a critical area of oncology but also validates its platform and analytical capabilities in the eyes of established research institutions.

Tempus also boasts partnerships with leading oncology hubs and health systems, like the American Society of Clinical Oncology and Mayo Clinic. Here's what it means: Tempus is facing off against ...

“With Tempus’ unmatched expertise, depth, and broad reach, this collaboration strengthens our shared mission to revolutionize patient care and drive breakthroughs in the field of oncology.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology ...

In 2022 and 2023, Tempus AI reported year-over-year growth in its oncology NGS tests delivered of 53% and 48%, respectively. Should the company report a further decline in 2024 and the subsequent ...

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology ...